Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Payer and Reimbursement Considerations for Bispecific Therapies
Experts discuss how payer and reimbursement considerations affect access to bispecific therapies in different practice settings.
EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology
EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care
EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access
EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations
EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies
EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology
EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies
EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy
EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions
EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration
Now Viewing
EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies
EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies
EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?
Video content above is prompted by the following:
How do payer and reimbursement considerations affect access to bispecific therapies in different practice settings?
Related Videos
Related Content
